Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 9/20 | 0.64 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017330 | 0.91 | SLC6A5 (0.74) | SLC6A5TAOK1TAOK3LMNATP53 | |
| SCHEMBL5022176 | 0.91 | SLC6A5 (0.77) | SLC6A5TAOK1TAOK3LMNATP53 | |
| SCHEMBL5017438 | 0.90 | SLC6A5 (0.78) | SLC6A5TAOK1TAOK3LMNATP53 | |
| SCHEMBL16233251 | 0.88 | SLC6A5 (0.83) | SLC6A5LMNATP53HTR2AP2RX3 | |
| SCHEMBL16233198 | 0.84 | SLC6A5 (0.57) | SLC6A5LMNAOPRM1OPRD1 | |
| SCHEMBL6013403 | 0.84 | SLC6A5 (0.89) | SLC6A5TAOK1TAOK3LMNATP53 | |
| SCHEMBL16233209 | 0.82 | SLC6A5 (0.62) | SLC6A5LMNATP53THRBHTR2A | |
| SCHEMBL16233201 | 0.79 | SLC6A5 (0.59) | SLC6A5TAOK1TAOK3LMNAHPGD | |
| SCHEMBL16233223 | 0.78 | SLC6A5 (0.52) | SLC6A5TAOK1TAOK3LMNAALDH1A1 | |
| SCHEMBL5017542 | 0.78 | SLC6A5 (1.00) | SLC6A5LMNATP53KDM4EHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | SLC6A5 1714/4885TAOK1 3998/4885TAOK3 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.